The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 03, 2017

Filed:

May. 20, 2016
Applicant:

Csl Limited, Parkville, AU;

Inventors:

Andrew Donald Nash, Kew, AU;

Manuel Baca, Gaithersburg, MD (US);

Louis Jerry Fabri, Diamond Creek, AU;

Dennis Zaller, Scotch Plains, NJ (US);

William R. Strohl, Bridgewater, NJ (US);

Zhiqiang An, Ambler, PA (US);

Assignee:

CSL Limited, Victoria, AU;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); C07K 16/28 (2006.01); C12P 21/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); C12P 21/005 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/71 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/43 (2013.01);
Abstract

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.


Find Patent Forward Citations

Loading…